Grail Shares Surge 33% as FDA Hints Favorably on Galleri — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Grail shares surged 33% Monday after the FDA posted briefing documents ahead of Wednesday's advisory committee meeting on its Galleri cancer detection test, suggesting the agency may take a favorable view
- Galleri is a blood test designed to detect many types of cancer early, when they can be treated more effectively
- FDA advisory committee meeting is scheduled for Wednesday to discuss the test; the agency isn't obligated to follow panel advice but typically does
- Galleri is already available as a laboratory-based diagnostic, but FDA approval would help lead to reimbursement from Medicare and other insurance payers
- Investors had been bidding up Grail's stock in anticipation of the meeting even before Monday's surge
Why it matters: Grail's 33% single-day surge reflects a market that sees Wednesday's advisory panel as a probable rubber stamp for FDA approval — which would convert Galleri from a self-pay lab test into a Medicare-reimbursable screening tool, potentially unlocking millions of patients and a far larger revenue stream.
Ask SkimNews
